Your shopping cart is currently empty

Trilaciclib is a short-acting, orally effective CDK4/6 inhibitor with IC₅₀ values of 1 nM and 4 nM respectively. It transiently and reversibly induces G1 cell cycle arrest, mitigates chemotherapy-induced myelosuppression, and enhances antitumour immunity, making it applicable across multiple cancers.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | - | In Stock | |
| 5 mg | $89 | - | In Stock | |
| 10 mg | $163 | - | In Stock | |
| 25 mg | $328 | - | In Stock | |
| 50 mg | $579 | - | In Stock | |
| 100 mg | $786 | - | In Stock | |
| 200 mg | $1,080 | - | In Stock |
| Description | Trilaciclib is a short-acting, orally effective CDK4/6 inhibitor with IC₅₀ values of 1 nM and 4 nM respectively. It transiently and reversibly induces G1 cell cycle arrest, mitigates chemotherapy-induced myelosuppression, and enhances antitumour immunity, making it applicable across multiple cancers. |
| Targets&IC50 | CDK6:4 nM, CDK4:1 nM |
| In vitro | Methods: HS68 cells were treated with Trilaciclib (10-3000nM, 24 hours), fixed and stained with propidium iodide and RNAse A, then analyzed using a Cyan ADP Analyzer. Results: After 24 hours of treatment with 300 nM trilaciclib, the proportion of HS68 cells in the G1 phase reached as high as 98%.[1] |
| In vivo | Method: FVB/N mice were orally administered Trilaciclib (50, 100, 150 mg/kg, single dose), followed by EdU injection to measure the proliferation of bone marrow Lineage-negative cells. Results: Trilaciclib exhibited a dose-dependent effect, effectively suppressing the proliferation of bone marrow HSPCs. [1] |
| Molecular Weight | 446.55 |
| Formula | C24H30N8O |
| Cas No. | 1374743-00-6 |
| Smiles | CN1CCN(CC1)c1ccc(Nc2ncc3cc4C(=O)NCC5(CCCCC5)n4c3n2)nc1 |
| Relative Density. | 1.46 g/cm3 (Predicted) |
| Storage | store at low temperature | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 4.5 mg/mL (10.08 mM) | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.